Balance Sheet
Accounts PayablesAccumulated ExpensesCash & Current InvestmentsCash & EquivalentsCurrent AssetsCurrent TaxesGoodwill & IntangiblesInventoryLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Non-Current AssetsPayablesProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zhengye Biotechnology Holding (ZYBT) Common Equity: 2022-2024

Historic Common Equity for Zhengye Biotechnology Holding (ZYBT) over the last 3 years, with Dec 2024 value amounting to $48.3 million.

  • Zhengye Biotechnology Holding's Common Equity rose 2.51% to $48.3 million in Q4 2024 from the same period last year, while for Dec 2024 it was $48.3 million, marking a year-over-year increase of 2.51%. This contributed to the annual value of $48.3 million for FY2024, which is 0.61% up from last year.
  • Per Zhengye Biotechnology Holding's latest filing, its Common Equity stood at $48.3 million for FY2024, which was up 0.61% from $48.0 million recorded in FY2023.
  • Zhengye Biotechnology Holding's Common Equity's 5-year high stood at $53.2 million during FY2022, with a 5-year trough of $48.0 million in FY2023.
  • In the last 3 years, Zhengye Biotechnology Holding's Common Equity had a median value of $48.3 million in 2024 and averaged $49.8 million.
  • Per our database at Business Quant, Zhengye Biotechnology Holding's Common Equity fell by 9.68% in 2023 and then grew by 0.61% in 2024.
  • Over the past 3 years, Zhengye Biotechnology Holding's Common Equity (Yearly) stood at $53.2 million in 2022, then fell by 9.68% to $48.0 million in 2023, then increased by 0.61% to $48.3 million in 2024.